Friday, January 29, 2021
Hoth Therapeutics, Inc., a biopharmaceutical company, today announced extending a research collaboration agreement with Weill Cornell Medicine to continue investigating the therapeutic mechanism of action and safety of HT-003, a novel retinoic acid metabolism blocking agent (RAMBA), for the treatment of acne. The 1-year agreement extension is based on positive results generated from the prior research agreement that support a therapeutic effect of HT-003 in key signaling pathways contributing to the development of acne.
The extended research collaboration will expand the scope of investigation to further understand the therapeutic mechanism of HT-003 for treatment of acne and other inflammatory skin diseases. The research will also explore safety of HT-003 in murine models. Dr. Jonathan Zippin, M.D., Ph.D., FAAD, Associate Professor of Dermatology at Weill Cornell Medicine and HOTH Senior Scientific Advisor, will be the Principal Investigator for the research collaboration.
Mr. Robb Knie, Chief Executive Officer of Hoth, commented, "We are very excited for the potential of HT-003 as an acne therapeutic based on the recent results generated by Dr. Jonathan Zippin and we are pleased to continue our collaboration with Weill Cornell Medicine."
